GetTopicDetailResponse(id=04d580395fc, topicName=耐藥患者, introduction=耐藥患者, content=null, image=null, comments=5, allHits=1121, url=https://h5.medsci.cn/topic?id=80395, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93870, tagList=[TagDto(tagId=93870, tagName=耐藥患者)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2162193, encodeId=fcc121621930b, content=癌癥疫苗與化療對HLA-A2陽性<a href='/topic/show?id=7003598934b' target=_blank style='color:#2F92EE;'>#晚期非小細(xì)胞肺癌#</a><a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治療#</a><a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>的隨機開放標(biāo)簽對照研究, objectTitle=Ann. Oncol | 癌癥疫苗與化療對HLA-A2陽性晚期非小細(xì)胞肺癌免疫治療耐藥患者的隨機開放標(biāo)簽對照研究：ATALANTE-1, objectType=article, longId=795520, objectId=bea5e9552083, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301010/1696948482253_6145188.png, objectUrl=/article/show_article.do?id=bea5e9552083, replyNumber=0, likeNumber=158, createdTime=2023-10-11, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bea5e9552083, moduleTitle=Ann. Oncol | 癌癥疫苗與化療對HLA-A2陽性晚期非小細(xì)胞肺癌免疫治療耐藥患者的隨機開放標(biāo)簽對照研究：ATALANTE-1, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bea5e9552083)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807569, encodeId=4c0d180e56919, content=<a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>, objectTitle=Hypertention：難治性高血壓與高血壓耐藥患者的不良結(jié)局比較, objectType=article, longId=205228, objectId=b25420522832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b25420522832, replyNumber=0, likeNumber=110, createdTime=2021-08-18, rootId=0, userName=ligang4439, userId=869698, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b25420522832, moduleTitle=Hypertention：難治性高血壓與高血壓耐藥患者的不良結(jié)局比較, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b25420522832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807568, encodeId=66ea180e56896, content=<a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>, objectTitle=乳腺癌病例：輔助內(nèi)分泌原發(fā)耐藥患者晚期一線化療后氟維司群維持治療的重要性, objectType=article, longId=182240, objectId=4ee518224089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee518224089, replyNumber=0, likeNumber=100, createdTime=2020-02-02, rootId=0, userName=ligang4439, userId=869698, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee518224089, moduleTitle=乳腺癌病例：輔助內(nèi)分泌原發(fā)耐藥患者晚期一線化療后氟維司群維持治療的重要性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4ee518224089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807567, encodeId=776d180e56713, content=<a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>, objectTitle=NX方案聯(lián)合化療是內(nèi)分泌耐藥患者的重要治療選擇, objectType=article, longId=178555, objectId=69951e8555fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69951e8555fb, replyNumber=0, likeNumber=90, createdTime=2019-12-03, rootId=0, userName=ligang4439, userId=869698, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69951e8555fb, moduleTitle=NX方案聯(lián)合化療是內(nèi)分泌耐藥患者的重要治療選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=69951e8555fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807566, encodeId=319f180e56653, content=<a href='/topic/show?id=04d580395fc' target=_blank style='color:#2F92EE;'>#耐藥患者#</a>, objectTitle=T790M突變檢測，實現(xiàn)EGFR TKI耐藥患者的精準(zhǔn)治療, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=94, createdTime=2018-06-07, rootId=0, userName=ligang4439, userId=869698, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突變檢測，實現(xiàn)EGFR TKI耐藥患者的精準(zhǔn)治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
